Israel - English - Ministry of Health

unipharm trading ltd, israel - fluphenazine decanoate - solution for injection - fluphenazine decanoate 25 mg/ml - fluphenazine - fluphenazine - fludecate is a long acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g. chronic schizophrenics).fluphenazine decanoate injection has not been shown effective in the management of behavioral complications in patients with mental retardation.

Israel - English - Ministry of Health

unipharm trading ltd, israel - haloperidol as decanoate - solution for injection - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - indicated for the maintenance treatment of schizophrenia and schizoaffective disorder in adult patients currently stabilized with oral haloperidol..

Israel - English - Ministry of Health

unipharm ltd, israel - tinidazole - tablets - tinidazole 500 mg - tinidazole - for the oral treatment of trichomonas vaginals infections of the genito urinary tract in both female and male. for the prevention of anerobic infections after gynocological operations and stomach operations.

Israel - English - Ministry of Health

unipharm ltd, israel - amisulpride - film coated tablets - amisulpride 100 mg - amisulpride - treatment of schizophrenia.

Israel - English - Ministry of Health

unipharm ltd, israel - amisulpride - film coated tablets - amisulpride 400 mg - amisulpride - treatment of schizophrenia.

Israel - English - Ministry of Health

unipharm ltd, israel - risedronic acid as sodium - tablets - risedronic acid as sodium 150 mg - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

Israel - English - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 10 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - English - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 20 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - English - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 40 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - English - Ministry of Health

unipharm ltd, israel - clomipramine hydrochloride - tablets - clomipramine hydrochloride 25 mg - non selective monoamine reuptake inhibitors - depression of varying origin.in children and adolescents there is not sufficient evidence of safety and efficacy of maronil in the treatment of depressive states of varying aetiology and symptomatology. the use of maronil in children and adolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes.no experience is available in children younger than 5 years of age.